$GeoVax Labs (GOVX.US)$ TLDR; They are working on a long-ter...
$GeoVax Labs (GOVX.US)$ TLDR; They are working on a long-term and better Covid-19 vaccine, which wont require a booster like Pvitzer.
———————
Personal opinion:
Covid is still around and a Vaccine that doesn’t degrade over time like Pfizter and Modena would put Covid behind us. We could vaccinate children with it like we do for Tethanus, Hepathis, Tuberculosis, …
I am pretty sure governments will sponsor and buy it to reduce hospitalizations, and avoid to pay for boosters every year.
——————
Singapore reports in May from MOH:
The estimated number of COVID-19 cases in the week of 5 to 11 May 2024 rose to 25,900 cases, compared to 13,700 cases in the previous week. The average daily COVID-19 hospitalisations rose to about 250 from 181 the week before, while the average daily Intensive Care Unit (ICU) cases remained low at three cases compared to two cases in the previous week.
———————
From Yahoo news
GEO-CM04S1 is based on GeoVax's MVA viral vector platform, which supports the presentation of multiple vaccine antigens to the immune system in a single dose. GEO-CM04S1 encodes for both the spike (S) and nucleocapsid (N) antigens of SARS-CoV-2 and is specifically designed to induce both antibody and T-cell responses to those parts of the virus less likely to mutate over time. The more broadly functional engagement of the immune system is designed to protect against severe disease caused by continually emerging variants of COVID-19. Vaccines of this format should not require frequent and repeated modification or updating.
GEO-CM04S1 is currently being evaluated in three ongoing Phase 2 clinical trials:
• As a primary vaccine in immunocompromised patients (with hematologic cancers receiving cell transplants or CAR-T therapy). ClinicalTrials.gov Identifier: NCT04977024. A recent presentation of unpublished data from the open-label portion of the trial indicates that GEO-CM04S1 is highly immunogenic in these patients, inducing both antibody responses, including neutralizing antibodies, and T-cell responses.
• As a booster vaccine in immunocompromised patients with chronic lymphocytic leukemia (CLL), a recognized high-risk group for whom current mRNA vaccines and monoclonal antibody (MAb) therapies appear inadequate relative to providing protective immunity. ClinicalTrials.gov Identifier: NCT05672355.
• As a booster vaccine for healthy adults who have previously received the Pfizer or Moderna mRNA vaccine. ClinicalTrials.gov Identifier: NCT04639466.
GEO-CM04S1 is currently being evaluated in three ongoing Phase 2 clinical trials:
• As a primary vaccine in immunocompromised patients (with hematologic cancers receiving cell transplants or CAR-T therapy). ClinicalTrials.gov Identifier: NCT04977024. A recent presentation of unpublished data from the open-label portion of the trial indicates that GEO-CM04S1 is highly immunogenic in these patients, inducing both antibody responses, including neutralizing antibodies, and T-cell responses.
• As a booster vaccine in immunocompromised patients with chronic lymphocytic leukemia (CLL), a recognized high-risk group for whom current mRNA vaccines and monoclonal antibody (MAb) therapies appear inadequate relative to providing protective immunity. ClinicalTrials.gov Identifier: NCT05672355.
• As a booster vaccine for healthy adults who have previously received the Pfizer or Moderna mRNA vaccine. ClinicalTrials.gov Identifier: NCT04639466.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
